Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer

TAŞKIN S., GÜNGÖR M., Ortac F., Oztuna D.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, cilt.288, sa.6, ss.1399-1403, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 288 Sayı: 6
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00404-013-2924-7
  • Dergi Adı: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1399-1403
  • Anahtar Kelimeler: Neoadjuvant chemotherapy, Ovarian cancer, Optimal cytoreduction, Survival, CARCINOMA, DEBULKING, DISEASE
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance